GlassScriptPhysician profile
Hong Xu
NPI 1922064625
$33,388.25
in general payments reported to CMS, 2019-2025
34 companies · $5,710 in 2025
The $5,710 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,813 · 2020: $1,360 · 2021: $3,204 · 2022: $5,723 · 2023: $4,679 · 2024: $5,900 · 2025: $5,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $193 · Consulting Fee: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,910.63 |
| Education | $193.03 |
| Consulting Fee | $185.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,373.70 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $4,617.39 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Janssen Biotech, INC. | $4,279.62 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $2,527.18 | 2019-2025 | |
| Ucb, INC. | $2,047.09 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $1,444.06 | 2019-2024 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $1,343.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,040.70 | 2019-2025 | Benlysta |
| Radius Health, INC. | $1,026.63 | 2019-2025 | Tymlos |
| Fidia Pharma USA INC. | $874.31 | 2019-2025 | Hym/Hyn, Hymhyn |
| Ani Pharmaceuticals, INC. | $849.73 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $735.02 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $706.90 | 2020-2025 | Ofev, Cyltezo |
| Mallinckrodt Enterprises LLC | $655.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $623.43 | 2021-2023 | Saphnelo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $572.81 | 2019-2025 | Actemra, Rituxan |
| Aurinia Pharma U.S., INC. | $407.30 | 2021-2024 | Lupkynis |
| Janssen Pharmaceuticals, INC | $360.82 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $284.07 | 2022-2025 | Orencia, Sotyktu |
| Pacira Therapeutics, INC. | $218.88 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $199.87 | 2019 | |
| Genzyme Corporation | $190.94 | 2020-2025 | |
| Sandoz INC. | $188.31 | 2023-2025 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $172.34 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $126.85 | 2022 | |
| Ferring Pharmaceuticals INC. | $102.23 | 2021-2023 | Euflexxa |
| Sobi, INC | $93.03 | 2022-2025 | |
| Hikma Pharmaceuticals USA | $86.16 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $53.82 | 2022-2025 | Strensiq |
| Celgene Corporation | $53.51 | 2019 | |
| Fresenius Kabi USA, LLC | $43.71 | 2025 | |
| Medexus Pharma, INC. | $42.14 | 2019 | |
| Almatica Pharma LLC | $23.14 | 2025 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $22.75 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.